Home > Healthcare > Medical Devices > Therapeutic Devices > gastrointestinal bleeding treatment market
Get a free sample of Gastrointestinal Bleeding Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Gastrointestinal Bleeding Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Based on product, the market is segmented into endoscopic hemostatic devices, closure devices, and other products. The endoscopic hemostatic devices segment is further divided into endoscopic mechanical devices and endoscopic thermal devices. The endoscopic hemostatic devices segment dominated the market with revenue of USD 498.8 million in 2023.
Based on GI tract division, the gastrointestinal bleeding treatment market is segmented into upper GI tract and lower GI tract. The upper GI tract segment held a dominant market share of 72.4% in 2023.
Based on onset, the gastrointestinal bleeding treatment market is classified into acute and chronic. The acute segment is expected to reach USD 1.1 billion by 2032.
Based on end-use, the gastrointestinal bleeding treatment market is classified into hospitals, ambulatory surgical centers, and other end-users. The hospitals segment dominated the market in 2023 and is anticipated to grow at 7.8% CAGR between 2024- 2032.
In 2023, North America held a market share of 41.6% in the global gastrointestinal bleeding treatment market and is expected to reach USD 635.7 million by 2032.
Gastrointestinal bleeding treatment market size was USD 808 million in 2023 and is expected to register 7.9% CAGR from 2024-2032 owing to the rising cases of gastrointestinal disorders such as peptic ulcers, gastritis, and colorectal cancer worldwide.
Gastrointestinal bleeding treatment industry from the endoscopic hemostatic devices segment recorded USD 498.8 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to their high efficacy and minimally invasive nature.
North America gastrointestinal bleeding treatment industry held 41.6% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the high prevalence of gastrointestinal disorders in the region.
CONMED Corporation, Cook Group, ERBE Elektromedizin GmbH, Medtronic PLC, Olympus Corporation, Ovesco Endoscopy AG, Pfizer Inc., STERIS PLC, and US Medical Innovations, are some of the major gastrointestinal bleeding treatment companies worldwide.